Rhythm Pharmaceuticals Inc.(RYTM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RYTM Rhythm Pharmaceuticals Inc.

交易中 12-15 11:17:12 EST

114.00

+0.44

+0.39%

最高116.34	最低111.94	成交量29.70万
今开112.42	昨收113.56	日振幅3.88%
总市值76.08亿	流通市值60.89亿	总股本6,674万
成交额3,390万	换手率0.56%	流通股本5,342万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RYTM","market":"US","secType":"STK","nameCN":"Rhythm Pharmaceuticals Inc.","latestPrice":114,"timestamp":1765815426356,"preClose":113.56,"halted":0,"volume":296983,"delay":0,"floatShares":53415100,"shares":66736056,"eps":-3.105726,"marketStatus":"交易中","change":0.44,"latestTime":"12-15 11:17:12 EST","open":112.42,"high":116.34,"low":111.9355,"amount":33903273.38751,"amplitude":0.038786,"askPrice":114.32,"askSize":205,"bidPrice":113.65,"bidSize":94,"shortable":3,"etf":0,"ttmEps":-3.105726,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1765832400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1507176000000,"exchange":"NASDAQ","adjPreClose":113.56,"preHourTrading":{"tag":"盘前","latestPrice":112.78,"preClose":113.56,"latestTime":"09:29 EST","volume":168,"amount":19031.49696,"timestamp":1765808954094},"postHourTrading":{"tag":"盘后","latestPrice":113.6,"preClose":113.56,"latestTime":"19:55 EST","volume":35167,"amount":4012265.2236,"timestamp":1765587315158},"volumeRatio":0.756582,"impliedVol":0.4738,"impliedVolPercentile":0.3},"requestUrl":"/m/hq/s/RYTM","defaultTab":"news","newsList":[{"id":"1184614665","title":"Rhythm Pharmaceuticals公布探索性第二阶段试验的初步数据，显示Setmelanotide在Prader-Willi综合症中展现了积极的疗效信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1184614665","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184614665?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:32","pubTimestamp":1765456337,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals公布探索性第二阶段试验的初步数据，显示Setmelanotide在Prader-Willi综合症中展现了积极的疗效信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"1103258053","title":"Rhythm Pharmaceuticals Inc.：安全性和耐受性结果与Setmelanotide公认的临床特征一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1103258053","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103258053?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:32","pubTimestamp":1765456335,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc.：安全性和耐受性结果与Setmelanotide公认的临床特征一致","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RYTM","BK4585","BK4588"],"gpt_icon":0},{"id":"1168371881","title":"Rhythm Pharmaceuticals将公布探索性第二阶段临床试验中Setmelanotide在普拉德-威利综合症中的初步数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1168371881","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168371881?lang=zh_cn&edition=full","pubTime":"2025-12-11 05:05","pubTimestamp":1765400748,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals将公布探索性第二阶段临床试验中Setmelanotide在普拉德-威利综合症中的初步数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","RYTM","BK4585"],"gpt_icon":0},{"id":"2585317281","title":"Rhythm Pharmaceuticals, Inc.跌2.13% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2585317281","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585317281?lang=zh_cn&edition=full","pubTime":"2025-11-21 22:31","pubTimestamp":1763735513,"startTime":"0","endTime":"0","summary":"北京时间2025年11月21日22时31分，Rhythm Pharmaceuticals, Inc.股票出现波动，股价大幅下挫2.13%。截至发稿，该股报98.52美元/股，成交量2.9421万股，换手率0.04%，振幅0.17%。Rhythm Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.19%。其相关个股中，Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 、Osr Holdings, Inc.、Sangamo Therapeutics, Inc.涨幅较大，Osr Holdings, Inc.、Telomir Pharmaceuticals, Inc.、Psyence Biomedical Ltd.较为活跃，换手率分别为30.70%、12.52%、10.86%，振幅较大的相关个股有Sangamo Therapeutics, Inc.、Osr Holdings, Inc.、Cue Biopharma, Inc.，振幅分别为21.25%、11.60%、11.08%。Rhythm Pharmaceuticals, Inc.公司简介：Rhythm Pharmaceuticals Inc 是一家商业阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511212231539777db1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511212231539777db1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","BK4139","RYTM"],"gpt_icon":0},{"id":"1123883252","title":"节奏制药宣布FDA延长针对获得性下丘脑肥胖患者的IMCIVREE（setmelanotide）审核期限","url":"https://stock-news.laohu8.com/highlight/detail?id=1123883252","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123883252?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:11","pubTimestamp":1763572311,"startTime":"0","endTime":"0","summary":"11月7日 - 节奏制药公司宣布，FDA已延长针对获得性下丘脑肥胖患者的IMCIVREE®（setmelanotide）的审核期限。FDA设定了更新后的PDUFA目标日期为2026年3月20日。FDA在10月要求对获得性下丘脑肥胖的3期试验的有效性数据进行额外的敏感性分析。此次重大修订并未包含任何与setmelanotide的安全性或生产相关的信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","RYTM","BK4139"],"gpt_icon":0},{"id":"1174636319","title":"Rhythm Pharmaceuticals股价在盘前下跌3.5%，因美国FDA延长对其脑损伤相关肥胖药物的审查","url":"https://stock-news.laohu8.com/highlight/detail?id=1174636319","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174636319?lang=zh_cn&edition=full","pubTime":"2025-11-07 21:38","pubTimestamp":1762522702,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals股价在盘前下跌3.5%，因美国FDA延长对其脑损伤相关肥胖药物的审查。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","RYTM","BK4588","BK4139"],"gpt_icon":0},{"id":"1196060143","title":"Rhythm Pharmaceuticals Inc.: 重大修订未涉及Setmelanotide的安全性或生产信息","url":"https://stock-news.laohu8.com/highlight/detail?id=1196060143","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196060143?lang=zh_cn&edition=full","pubTime":"2025-11-07 20:36","pubTimestamp":1762518986,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc.: 重大修订未涉及Setmelanotide的安全性或生产信息","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"1128479106","title":"Rhythm Pharmaceuticals：10月FDA要求对获得性下丘脑肥胖症三期试验的疗效数据进行额外敏感性分析","url":"https://stock-news.laohu8.com/highlight/detail?id=1128479106","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128479106?lang=zh_cn&edition=full","pubTime":"2025-11-07 20:36","pubTimestamp":1762518981,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals：10月FDA要求对获得性下丘脑肥胖症三期试验的疗效数据进行额外敏感性分析","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4585","RYTM"],"gpt_icon":0},{"id":"1134985244","title":"Rhythm Pharmaceuticals宣布FDA延长Imcivree®（Setmelanotide）对获得性下丘脑肥胖患者审查期限","url":"https://stock-news.laohu8.com/highlight/detail?id=1134985244","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134985244?lang=zh_cn&edition=full","pubTime":"2025-11-07 20:32","pubTimestamp":1762518742,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals宣布FDA延长Imcivree®（Setmelanotide）对获得性下丘脑肥胖患者审查期限","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","RYTM","BK4139","BK4585"],"gpt_icon":0},{"id":"1106824522","title":"Rhythm Pharmaceuticals在加拿大五个省份及联邦非保险健康福利计划下宣布Imcivree® (Setmelanotide)的公共报销","url":"https://stock-news.laohu8.com/highlight/detail?id=1106824522","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106824522?lang=zh_cn&edition=full","pubTime":"2025-11-06 05:05","pubTimestamp":1762376731,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals在加拿大五个省份及联邦非保险健康福利计划下宣布Imcivree® (Setmelanotide)的公共报销","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RYTM","BK4588","BK4585"],"gpt_icon":0},{"id":"2558068172","title":"Rhythm Pharmaceuticals, Inc.2025财年第二财季实现净利润-46.63百万美元，同比减少44.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558068172","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558068172?lang=zh_cn&edition=full","pubTime":"2025-08-11 00:01","pubTimestamp":1754841673,"startTime":"0","endTime":"0","summary":"8月11日，Rhythm Pharmaceuticals, Inc.公布财报，公告显示公司2025财年第二财季净利润为-46.63百万美元，同比减少44.54%；其中营业收入为48.50百万美元，同比增加66.78%，每股基本收益为-0.75美元。机构评级：截至2025年8月11日，当前有14家机构对Rhythm Pharmaceuticals, Inc.目标价做出预测，其中目标均价为112.14美元，其中最低目标价为95.00美元，最高目标价为135.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000250a48056eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000250a48056eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RYTM"],"gpt_icon":0},{"id":"2555082934","title":"Rhythm Pharmaceuticals, Inc.7月28日成交额为5585.15万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555082934","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555082934?lang=zh_cn&edition=full","pubTime":"2025-07-29 13:56","pubTimestamp":1753768585,"startTime":"0","endTime":"0","summary":"美东时间2025年7月28日，Rhythm Pharmaceuticals, Inc.成交额为5585.15万美元，成交额较昨日增加60.51%，当日成交量为65.38万股。Rhythm Pharmaceuticals, Inc.于2025年7月28日跌0.89%，报85.68美元，该股过去5个交易日跌3.33%，年初至今涨53.05%，过去60日涨31.43%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-07-28|5585.15万|60.51%|65.38万|#|2025-07-25|3479.70万|2.57%|40.28万|#|2025-07-24|3392.38万|-27.50%|38.86万|#|2025-07-23|4679.09万|-3.90%|53.26万|#|2025-07-22|4868.86万|-17.95%|55.16万|Rhythm Pharmaceuticals Inc 是一家商业阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729135629a6c73136&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729135629a6c73136&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RYTM","BK4585","BK4139","BK4588"],"gpt_icon":0},{"id":"2554153287","title":"Rhythm Pharmaceuticals, Inc.7月25日成交额为3479.70万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554153287","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554153287?lang=zh_cn&edition=full","pubTime":"2025-07-26 13:49","pubTimestamp":1753508963,"startTime":"0","endTime":"0","summary":"美东时间2025年7月25日，Rhythm Pharmaceuticals, Inc.成交额为3479.70万美元，成交额较昨日增加2.57%，当日成交量为40.28万股。Rhythm Pharmaceuticals, Inc.于2025年7月25日跌0.94%，报86.45美元，该股过去5个交易日跌3.08%，年初至今涨54.43%，过去60日涨32.55%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-07-25|3479.70万|2.57%|40.28万|#|2025-07-24|3392.38万|-27.50%|38.86万|#|2025-07-23|4679.09万|-3.90%|53.26万|#|2025-07-22|4868.86万|-17.95%|55.16万|#|2025-07-21|5934.35万|6.16%|66.81万|Rhythm Pharmaceuticals Inc 是一家商业阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726134926a464594b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726134926a464594b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","RYTM","BK4588","BK4139"],"gpt_icon":0},{"id":"2554756982","title":"Rhythm Pharmaceuticals, Inc.7月24日成交额为3392.38万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554756982","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554756982?lang=zh_cn&edition=full","pubTime":"2025-07-25 13:39","pubTimestamp":1753421950,"startTime":"0","endTime":"0","summary":"美东时间2025年7月24日，Rhythm Pharmaceuticals, Inc.成交额为3392.38万美元，成交额较昨日减少27.50%，当日成交量为38.86万股。Rhythm Pharmaceuticals, Inc.于2025年7月24日跌0.61%，报87.27美元，该股过去5个交易日跌3.76%，年初至今涨55.89%，过去60日涨35.49%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-07-24|3392.38万|-27.50%|38.86万|#|2025-07-23|4679.09万|-3.90%|53.26万|#|2025-07-22|4868.86万|-17.95%|55.16万|#|2025-07-21|5934.35万|6.16%|66.81万|#|2025-07-18|5589.79万|-7.81%|62.45万|Rhythm Pharmaceuticals Inc 是一家商业阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725133919a4629e18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725133919a4629e18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RYTM","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"2553129960","title":"Rhythm Pharmaceuticals, Inc.7月22日成交额为4868.86万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553129960","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553129960?lang=zh_cn&edition=full","pubTime":"2025-07-23 13:42","pubTimestamp":1753249340,"startTime":"0","endTime":"0","summary":"美东时间2025年7月22日，Rhythm Pharmaceuticals, Inc.成交额为4868.86万美元，成交额较昨日减少17.95%，当日成交量为55.16万股。Rhythm Pharmaceuticals, Inc.于2025年7月22日跌0.91%，报87.82美元，该股过去5个交易日跌1.72%，年初至今涨56.88%，过去60日涨39.46%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-07-22|4868.86万|-17.95%|55.16万|#|2025-07-21|5934.35万|6.16%|66.81万|#|2025-07-18|5589.79万|-7.81%|62.45万|#|2025-07-17|6063.24万|-8.61%|66.43万|#|2025-07-16|6634.50万|-12.58%|72.74万|Rhythm Pharmaceuticals Inc 是一家商业阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723134226a6bc82be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723134226a6bc82be&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","RYTM","BK4139"],"gpt_icon":0},{"id":"2550428653","title":"Rhythm Pharmaceuticals, Inc.盘中异动 早盘股价大涨16.67%报76.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550428653","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550428653?lang=zh_cn&edition=full","pubTime":"2025-07-09 21:31","pubTimestamp":1752067911,"startTime":"0","endTime":"0","summary":"北京时间2025年07月09日21时31分，Rhythm Pharmaceuticals, Inc.股票出现异动，股价大幅拉升16.67%。Rhythm Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.29%。Rhythm Pharmaceuticals, Inc.公司简介：Rhythm Pharmaceuticals Inc 是一家商业阶段的生物制药公司。消息层面，截至21时31分，《Leerink Partners首予Rhythm Pharmaceuticals买入评级，目标价88美元》资讯为影响Rhythm Pharmaceuticals, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709213152a69f8c3e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709213152a69f8c3e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","RYTM","BK4139"],"gpt_icon":0},{"id":"2518276046","title":"Rhythm Pharmaceuticals, Inc.盘中异动 早盘快速下挫5.01%报48.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518276046","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518276046?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:30","pubTimestamp":1741617055,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时30分，Rhythm Pharmaceuticals, Inc.股票出现异动，股价大幅下挫5.01%。Rhythm Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.15%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Aeon Biopharma, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Aeon Biopharma, Inc.较为活跃，换手率分别为3457.49%、730.68%、517.45%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.，振幅分别为41.36%、40.33%、40.24%。Rhythm Pharmaceuticals, Inc.公司简介：Rhythm Pharmaceuticals Inc 是一家生物制药公司，从事罕见病治疗方法的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223055964044b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223055964044b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RYTM","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"2517456009","title":"大摩：假定Rhythm Pharmaceuticals(RYTM.US)增持评级, 目标价由72.00美元调整至72.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517456009","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517456009?lang=zh_cn&edition=full","pubTime":"2025-03-08 01:53","pubTimestamp":1741369983,"startTime":"0","endTime":"0","summary":"大摩：假定Rhythm Pharmaceuticals(RYTM.US)增持评级, 目标价由72.00美元调整至72.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08015348605007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RYTM"],"gpt_icon":0},{"id":"2517404949","title":"Stifel：重申Rhythm Pharmaceuticals(RYTM.US)买入评级, 目标价78.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517404949","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517404949?lang=zh_cn&edition=full","pubTime":"2025-03-06 02:01","pubTimestamp":1741197678,"startTime":"0","endTime":"0","summary":"Stifel：重申Rhythm Pharmaceuticals(RYTM.US)买入评级, 目标价78.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06020148550854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RYTM"],"gpt_icon":0},{"id":"2516480445","title":"Rhythm Pharmaceuticals, Inc.2024财年实现净利润-2.61亿美元，同比减少41.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516480445","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516480445?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:00","pubTimestamp":1740931238,"startTime":"0","endTime":"0","summary":"3月3日，Rhythm Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为-2.61亿美元，同比减少41.08%；其中营业收入为1.30亿美元，同比增加67.89%，每股基本收益为-4.34美元。机构评级：截至2025年3月3日，当前有11家机构对Rhythm Pharmaceuticals, Inc.目标价做出预测，其中目标均价为74.73美元，其中最低目标价为60.00美元，最高目标价为94.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000058abe4aca5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000058abe4aca5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RYTM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.rhythmtx.com","stockEarnings":[{"period":"1week","weight":0.0857},{"period":"1month","weight":0.1597},{"period":"3month","weight":0.1802},{"period":"6month","weight":0.8054},{"period":"1year","weight":1.0395},{"period":"ytd","weight":1.0286}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Rhythm Pharmaceuticals, Inc.是一家特拉华州的公司，成立于2013年2月。该公司是一家全球性、商业阶段的生物制药公司，致力于改变患有罕见神经内分泌疾病的患者及其家人的生活。该公司专注于推进黑皮质素-4受体激动剂，包括他们的主要资产IMCIVREE，作为一种精准药物，旨在治疗由罕见的MC4R通路疾病引起的食欲亢进和严重肥胖。","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.053118},{"month":2,"riseRate":0.375,"avgChangeRate":-0.043141},{"month":3,"riseRate":0.125,"avgChangeRate":-0.055987},{"month":4,"riseRate":0.625,"avgChangeRate":0.023443},{"month":5,"riseRate":0.25,"avgChangeRate":-0.062002},{"month":6,"riseRate":0.5,"avgChangeRate":0.046517},{"month":7,"riseRate":0.5,"avgChangeRate":0.281728},{"month":8,"riseRate":0.75,"avgChangeRate":0.239414},{"month":9,"riseRate":0.375,"avgChangeRate":-0.040591},{"month":10,"riseRate":0.375,"avgChangeRate":-0.015139},{"month":11,"riseRate":0.777778,"avgChangeRate":0.136999},{"month":12,"riseRate":0.666667,"avgChangeRate":0.047959}],"exchange":"NASDAQ","name":"Rhythm Pharmaceuticals Inc.","nameEN":"Rhythm Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rhythm Pharmaceuticals Inc.(RYTM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Rhythm Pharmaceuticals Inc.(RYTM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Rhythm Pharmaceuticals Inc.,RYTM,Rhythm Pharmaceuticals Inc.股票,Rhythm Pharmaceuticals Inc.股票老虎,Rhythm Pharmaceuticals Inc.股票老虎国际,Rhythm Pharmaceuticals Inc.行情,Rhythm Pharmaceuticals Inc.股票行情,Rhythm Pharmaceuticals Inc.股价,Rhythm Pharmaceuticals Inc.股市,Rhythm Pharmaceuticals Inc.股票价格,Rhythm Pharmaceuticals Inc.股票交易,Rhythm Pharmaceuticals Inc.股票购买,Rhythm Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rhythm Pharmaceuticals Inc.(RYTM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Rhythm Pharmaceuticals Inc.(RYTM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}